ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

... And DNA vaccine pact with Inovio

November 13, 2006 | APPEARED IN VOLUME 84, ISSUE 46

Wyeth has licensed Inovio Biomedical's DNA delivery technology for vaccines for an up-front fee of $4.5 million. Wyeth will also pay undisclosed license maintenance fees, research support payments, and up to $60 million in milestone payments. Inovio says its MedPulser electroporation technology has been shown in primate studies to sharply boost the immune response to DNA vaccines compared with the response to DNA plasmid delivered via standard injection.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment